25I-NB3OMe

Clinical data
ATC code	none
Identifiers
IUPAC name 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(3-methoxyphenyl)methyl]ethanamine
CAS Number	1566571-40-1 Y
PubChem CID	118796422
ChemSpider	52085501 Y
UNII	490QN6U1OF
Chemical and physical data
Formula	C18H22INO3
Molar mass	427.282 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=CC=CC(=C1)CNCCC2=CC(=C(C=C2OC)I)OC
InChI InChI=1S/C18H22INO3/c1-21-15-6-4-5-13(9-15)12-20-8-7-14-10-18(23-3)16(19)11-17(14)22-2/h4-6,9-11,20H,7-8,12H2,1-3H3 Key:CJTZKPLDKCBUAF-UHFFFAOYSA-N

25I-NB3OMe (2C-I-NB3OMe, NB3OMe-2C-I) is a derivative of the phenethylamine hallucinogen 2C-I, which acts as a highly potent partial agonist for the human 5-HT_2A receptor.^[1][2]

Legality[edit]

United Kingdom[edit]

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.^[3]

United States[edit]

25I-NB3OMe is not a controlled substance, but is a positional isomer of 25I-NBOMe and thus may be considered a Schedule I drug under the Federal Analogue Act, meaning that it would be subject to the same penalties for possession, distribution, and manufacture as 25I-NBOMe.

References[edit]